Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Drug Release Studies of SC-514 PLGA Nanoparticles

View through CrossRef
A major problem associated with prostate cancer treatment is the development of drug resistance. The development of drug resistance often leads to prostate cancer metastasis and prostate cancer-targeted drug delivery systems can be utilized to address this problem. Traditional drug delivery systems have many challenges, including the inability to control the drug release rate, target site inaccuracy, susceptibility to the microenvironment, poor drug solubility, and cytotoxicity of chemotherapeutics to non-malignant cells. As a result, there is an urgent need to formulate and functionalize a drug delivery system that better controls drug release. This study was designed to quantify the release of SC-514 from SC-514 Polylactic-Co-Glycolic Acid (PLGA) nanoparticles and conjugate SC-514-PLGA coated nanoparticles with the NF- κβ antibody, as well as fats. This study further explored new methods to quantify the release of SC-514 drug from the SC-514-PLGA coated nanoparticles after utilizing Liquid Chromatography–Mass Spectrometry (LC-MS) as the standard method to quantify SC-514 drug released. After quantification was completed, cell viability studies indicated that the ligand conjugated nanoparticles demonstrated a considerable ability to reduce tumor growth and SC-514 drug toxicity in the PC-3 cell line. The prepared drug delivery systems also possessed a significantly lower toxicity (P<0.05), bettered controlled-release behaviors in prostate cancer, and increased the solubility of SC-514 in comparison to free SC-514. SC-514 released from SC-514-PLGA, SC-514-PLGA-NF- κβAb, and SC-514-PLGA-Fat nanoparticles, significantly inhibited tumor growth when compared to that of free SC-514. The anti-cancer therapeutic effects of SC-514 were improved through the encapsulation of SC-514 with a PLGA polymer. The functionalized SC-514-PLGA nanoparticles can further control burst release. The new methods utilized in this study for quantifying drug release, may prove to be as effective as the current standard methods, such as LC/MS.
Title: Drug Release Studies of SC-514 PLGA Nanoparticles
Description:
A major problem associated with prostate cancer treatment is the development of drug resistance.
The development of drug resistance often leads to prostate cancer metastasis and prostate cancer-targeted drug delivery systems can be utilized to address this problem.
Traditional drug delivery systems have many challenges, including the inability to control the drug release rate, target site inaccuracy, susceptibility to the microenvironment, poor drug solubility, and cytotoxicity of chemotherapeutics to non-malignant cells.
As a result, there is an urgent need to formulate and functionalize a drug delivery system that better controls drug release.
This study was designed to quantify the release of SC-514 from SC-514 Polylactic-Co-Glycolic Acid (PLGA) nanoparticles and conjugate SC-514-PLGA coated nanoparticles with the NF- κβ antibody, as well as fats.
This study further explored new methods to quantify the release of SC-514 drug from the SC-514-PLGA coated nanoparticles after utilizing Liquid Chromatography–Mass Spectrometry (LC-MS) as the standard method to quantify SC-514 drug released.
After quantification was completed, cell viability studies indicated that the ligand conjugated nanoparticles demonstrated a considerable ability to reduce tumor growth and SC-514 drug toxicity in the PC-3 cell line.
The prepared drug delivery systems also possessed a significantly lower toxicity (P<0.
05), bettered controlled-release behaviors in prostate cancer, and increased the solubility of SC-514 in comparison to free SC-514.
SC-514 released from SC-514-PLGA, SC-514-PLGA-NF- κβAb, and SC-514-PLGA-Fat nanoparticles, significantly inhibited tumor growth when compared to that of free SC-514.
The anti-cancer therapeutic effects of SC-514 were improved through the encapsulation of SC-514 with a PLGA polymer.
The functionalized SC-514-PLGA nanoparticles can further control burst release.
The new methods utilized in this study for quantifying drug release, may prove to be as effective as the current standard methods, such as LC/MS.

Related Results

Karakteristik Poli Asam Laktat Glikolat (Kajian Rasio Asam Laktat Limbah Aren-Asam Glikolat)
Karakteristik Poli Asam Laktat Glikolat (Kajian Rasio Asam Laktat Limbah Aren-Asam Glikolat)
Polimer Poli Asam Laktat Glikolat (PLGA) merupakan salah satu jenis polimer yang telah disetujui FDA dan EMA untuk penggunaan biomedik. Kelebihan PLGA yaitu biokompatibilitas, biod...
Superior performance of biocomposite nanoparticles PLGA-RES in protecting oocytes against vitrification stimuli
Superior performance of biocomposite nanoparticles PLGA-RES in protecting oocytes against vitrification stimuli
Irreversible cryogenic damage caused by oocyte vitrification limits its widespread use in female fertility preservation. In recent years, nanoparticles (NPs) have gained great atte...
Antimicrobial activity of ciprofloxacin-coated gold nanoparticles on selected pathogens
Antimicrobial activity of ciprofloxacin-coated gold nanoparticles on selected pathogens
Antibiotic resistance amongst bacterial pathogens is a crisis that has been worsening over recent decades, resulting in serious and often fatal infections that cannot be treated by...
Therapeutic Effect of Cisplatin-Loaded Polymeric Nanoparticles and Nimotuzumab Combination in Human Glioblastoma Cells
Therapeutic Effect of Cisplatin-Loaded Polymeric Nanoparticles and Nimotuzumab Combination in Human Glioblastoma Cells
Abstract Objective This study evaluated the combined therapeutic effects of cisplatin-loaded PEG-PLGA nanoparticles (CIS-PEG-PLGA) and nimotuzumab (NIMO) on glioblastoma (...
An In Situ Gel-Forming Heparin-Conjugated PLGA-PEG-PLGA Copolymer
An In Situ Gel-Forming Heparin-Conjugated PLGA-PEG-PLGA Copolymer
Novel heparin-conjugated PLGA-PEG-PLGA hydrogels were prepared via Michael-type addition between thiolated heparin and PLGA-PEG-PLGA diacrylate. The thiolated heparin (HP-SH) was c...
Rat Cartilage Repair Using Nanophase PLGA/HA Composite and Mesenchymal Stem Cells
Rat Cartilage Repair Using Nanophase PLGA/HA Composite and Mesenchymal Stem Cells
Biodegradable polymer/bioceramic composite poly(lactide- coglycolide)/hydroxyapatite(PLGA/HA) was studied for bone tissue engineering. The PLGA/HA composite was evaluated as a scaf...
Study on Prevention of Postoperative Abdominal Adhesions with PLGA Nanofiber Membrane
Study on Prevention of Postoperative Abdominal Adhesions with PLGA Nanofiber Membrane
AbstractObjective: To evaluate the effectiveness of poly (lactic-co-glycolic acid) (PLGA) nanofiber membrane on prevention of postoperative abdominal adhesion. Methods: PLGA nanofi...

Back to Top